The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

Trial Profile

The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Interstitial lung diseases
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LOTUSS
  • Sponsors Genentech; InterMune
  • Most Recent Events

    • 01 Jul 2016 Results published in The Journal of Rheumatology
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 29 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top